Pemetrexed (PEM) maintenance versus observation (OBS) in patients (pts) with advanced urothelial carcinoma (aUC) who completed first-line (1L) platinum-based chemotherapy (CTx) without disease progression (PREMIER, KCSG GU16-05).

Authors

Inkeun Park

Asan Medical Center, Seoul, South Korea

Inkeun Park , Shinkyo Yoon , Il Hwan Kim , Kwonoh Park , Suee Lee , Bhumsuk Keam , Joo-Hwan Park , Jin Young Kim , Yoon Ji Choi , Byeong Seok Sohn , Jae-Lyun Lee

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2023 ASCO Genitourinary Cancers Symposium

bookmark_border

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Long-term follow-up from the JAVELIN Bladder 100 trial in subgroups defined by 1L chemotherapy regimen and analysis of overall survival (OS) from start of 1L chemotherapy.

First Author: Srikala S. Sridhar

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

First Author: Petros Grivas

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.

First Author: Benjamin Miron

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Outcomes by complete response to first-line pembrolizumab or platinum-based chemotherapy in advanced urothelial carcinoma (UC) in KEYNOTE-361.

First Author: Ozgur Ozyilkan